Drugs / REMTOLUMAB
Trials 5 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT01853033 | Jul 2013 → May 2014 | rheumatoid arthritis | AbbVie | Completed | No outcome recorded |
| Phase 24 trials | ||||||
| Phase 2 | NCT02429895 | Oct 2015 → May 2016 | psoriatic arthritis | AbbVie | Terminated | No outcome recorded |
| Phase 2 | NCT02349451 | Apr 2015 → Jul 2016 | psoriatic arthritis | AbbVie | Completed | No outcome recorded |
| Phase 2 | NCT02433340 | Apr 2015 → May 2016 | rheumatoid arthritis | AbbVie | Completed | No outcome recorded |
| Phase 2 | NCT02141997 | Jul 2014 → Sep 2015 | rheumatoid arthritis | AbbVie | Completed | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 8 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | REMTOLUMAB | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297863 ↗ |
| Known as | A-1230717 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297863 ↗ |
| Known as | ABT-122 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02433340 ↗ |
| Action | Inhibit | “ABT-122 is a dual-variable domain immunoglobulin that neutralizes both tumor necrosis factor-α and interleukin-17A” PMID 28744796 ↗ May 20181“Interleukin 17A inhibitor” CHEMBL4297863 ↗ |
| Modality | Protein / enzyme biologic | “ABT-122 is a dual-variable domain immunoglobulin” PMID 28744796 ↗ May 2018 |
| Route | Subcutaneous | “ABT-122 or placebo will be administered as subcutaneous (under the skin) injections in three dosing groups.” NCT01853033 ↗ |
| Target | IL17A | “Interleukin 17A inhibitor” CHEMBL4297863 ↗ |
| Target | TNF | “ABT-122 is a novel dual variable domain immunoglobulin that selectively and simultaneously targets human TNF and IL-17A.” PMID 28941216 ↗ Nov 2017 |